Popular on EntSun
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 275
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 247
- Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick - 196
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform - 179
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide - 178
- "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society - 155
- Donna Cardellino Manager/Facilitator Signs Justin Jeansonne Country Singer-Songwriter To Exclusive Management Deal For Global Music Expansion - 139
- VDG Virtuoso Emerges as a New-Model Independent Industry Figure Blending Artist, Executive, and Infrastructure Builder - 136
- Phillip E. Walker's Hollywood Actor Jobs Dec. 10-20, 2025 PRE-TOUR Launches with SweetestVacation.com at CulverCityFilmFestival.com & Closes in the IE - 130
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor - 118
Similar on EntSun
- AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
- $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
- U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
Metavalis Inc. Initiates Formation of Scientific Advisory Board for Non Viral Gene Therapy Asset
EntSun News/11079719
Bioengineering firm recruiting founding advisors in Lipid Physics, Hepatology, and Regulatory Affairs to guide its Smart LNP 3.0 platform and Dec 24th IP filing.
BRANSON, Mo. - EntSun -- Following the scheduled filing of foundational intellectual property for its Smart LNP 3.0 platform a novel biodegradable ionizable lipid polysarcosine conjugate Metavalis is moving to appoint four strategic partners to guide the asset through pre clinical validation and FDA Pre IND pathways.
"We are assembling a council of technical architects, not just observers," said Jordan Bekemeier, Founder of Metavalis. "Our platform is engineered to solve the Redosing Bottleneck in gene therapy for Crigler-Najjar Syndrome. We are seeking equity aligned partners who possess deep domain expertise in non viral delivery physics and regulatory strategy."
Open Advisory Seats:
Metavalis is currently accepting inquiries for the following strategic roles:
The LNP Architect (Formulation Science): Seeking Ph.D. leadership in biodegradable lipid kinetics and extra-hepatic delivery, specifically regarding Polysarcosine lipid conjugates.
The Clinical Lead (Hepatology): Seeking an M.D./Ph.D. with principal investigator experience in metabolic liver disease trials (CNS1/Urea Cycle Disorders).
More on EntSun News
The Regulatory Strategist (Compliance): Seeking former FDA CBER reviewers or regulatory consultants with specific expertise in non viral gene therapy IND applications.
The Polymer Chemist (Materials Science): Seeking expertise in Stealth polymer synthesis to replace PEG architectures.
About Metavalis Inc.
Metavalis Inc. is a biotechnology company focused on the development of non viral genetic medicines. The company integrates the Universal Constructor Protocol, a sovereign quantum neuromorphic AI architecture, to optimize biological delivery vectors.
Contact Information:
Qualified candidates and researchers interested in strategic partnership may contact the executive office directly.
You can also Apply on LinkedIn at:
https://www.linkedin.com/jobs/view/4327214946
Contact: Jordan Bekemeier, Founder & CEO
Email: jordan@metavalis.com
Website: https://metavalis.com/
Forward Looking Statements
This press release contains forward looking statements regarding the company's recruitment plans and investigational technologies. These statements are subject to risks and uncertainties.
"We are assembling a council of technical architects, not just observers," said Jordan Bekemeier, Founder of Metavalis. "Our platform is engineered to solve the Redosing Bottleneck in gene therapy for Crigler-Najjar Syndrome. We are seeking equity aligned partners who possess deep domain expertise in non viral delivery physics and regulatory strategy."
Open Advisory Seats:
Metavalis is currently accepting inquiries for the following strategic roles:
The LNP Architect (Formulation Science): Seeking Ph.D. leadership in biodegradable lipid kinetics and extra-hepatic delivery, specifically regarding Polysarcosine lipid conjugates.
The Clinical Lead (Hepatology): Seeking an M.D./Ph.D. with principal investigator experience in metabolic liver disease trials (CNS1/Urea Cycle Disorders).
More on EntSun News
- Orlando Hosts Largest Fashion Collaboration as The Fashion Hub Company Opens Its Doors in Downtown Orlando
- Circus Harmony's annual show "Misterioso" celebrates 25th anniversary weekends in February
- Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
- Waarom brand mentions in ChatGPT steeds belangrijker worden
- Destination: Scientology Shines with Team Spirit in Columbus at 2025 Dotcomm Awards
The Regulatory Strategist (Compliance): Seeking former FDA CBER reviewers or regulatory consultants with specific expertise in non viral gene therapy IND applications.
The Polymer Chemist (Materials Science): Seeking expertise in Stealth polymer synthesis to replace PEG architectures.
About Metavalis Inc.
Metavalis Inc. is a biotechnology company focused on the development of non viral genetic medicines. The company integrates the Universal Constructor Protocol, a sovereign quantum neuromorphic AI architecture, to optimize biological delivery vectors.
Contact Information:
Qualified candidates and researchers interested in strategic partnership may contact the executive office directly.
You can also Apply on LinkedIn at:
https://www.linkedin.com/jobs/view/4327214946
Contact: Jordan Bekemeier, Founder & CEO
Email: jordan@metavalis.com
Website: https://metavalis.com/
Forward Looking Statements
This press release contains forward looking statements regarding the company's recruitment plans and investigational technologies. These statements are subject to risks and uncertainties.
Source: Metavalis
0 Comments
Latest on EntSun News
- Custom Home Builder Connecticut Valley Homes Wins 2025 Home of the Year from the Modular Home Builders Association
- TAP Announces Open Auditions for 2026 Season
- Orchestra Manhattan and Orpheus Chamber Orchestra to Launch Community Concert Association Season
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
- Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
- Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
- Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth
- CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
- NEXO, the First AI Artist From 2045, Releases Cinematic Music Video for "STACK BAGS"
- Award Winning Comedian Returns to Diamond Mountain
- Goatimus Launches Dynamic Context: AI Prompt Engineering Gets Smarter
- Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
- Former San Francisco Top 40 DJ Releases Candid Memoir of Radio's TOP 40-dominant years
- RNHA Affirms Support for President Trump as Nation Marks Historic Victory for Freedom
- American Laser Study Club Announces 2026 Kumar Patel Prize in Laser Surgery Recipients: Ann Bynum, DDS, and Boaz Man, DVM
- Lineus Medical Completes UK Registration for SafeBreak® Vascular
- Creators' Rights Movement Advances Copyright Rights and Generational Ownership
- Canyons & Chefs Announces Revamped Homepage
- $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH